Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Risperidone and Olanzapine versus Another First Generation Antipsychotic in Patients with Schizophrenia Inadequately Responsive to First Generation Antipsychotics Pharmacopsychiatry, 03/19/12 Chen JJ et al. – Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a first–generation antipsychotic. Methods This study was an 8-week treatment, randomized, rater-blind, active-control study with 3 treatment arms. 48 patients, who showed inadequate response to 1 FGA, were enrolled and randomized into risperidone, olanzapine, or FGA (haloperidol or trifluoperazine) groups. They were blindly assessed with the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression Scale-Severity, and the Extrapyramidal Symptom Rating Scale (ESRS) at baseline and biweekly. Results All 3 groups demonstrated a significant decrease in the PANSS total, positive, and general scores from baseline to endpoint (p-values range from 0.003 to 0.021). There were no significant differences among the 3 groups in score changes. The olanzapine group had significant score reductions than the risperidone and FGAs groups in terms of the ESRS subjective total score and did not experience a significant increase in the dose of anticholinergics. The FGA group demonstrated that extrapyramidal syndrome (EPS) worsened under an increased dosage of anti-EPS drugs. Olanzapine was associated with significant body weight gain (2.69�4.0 kg, p=0.026), but there were no significant group differences on weight gain. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list Low maternal retinol as a risk factor for schizophrenia in adult offspring Schizophrenia Research, 03/02/12 Hierarchical Organization of Gamma and Theta Oscillatory Dynamics in Schizophrenia Biological Psychiatry, 02/24/12 Genetic and functional analysis of the gene encoding neurogranin in schizophrenia Schizophrenia Research, 02/08/12 ©1999-2012 MDLinx, Inc. This email was sent at the request of draurelromila1@gmail.com. Copyright ©2012 M3 USA. All Rights Reserved. M3 USA considers the privacy of its users to be of utmost importance and works to protect it. We will not sell or share your information with 3rd parties without your permission. For comprehensive information about the steps that M3 USA takes to respect your privacy, please read our Privacy Policy. This email has been sent by MDLinx, a division of M3 USA, 1215 17th St NW Washington, DC 20036 Tel: +1.202.293.2288 Fax: +1.202.293.1690